Jenna Mann

Dr. Jenna Mann

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JMJenna Mann
Jenna Mann
YSYves P. Starreveld
Yves P. Starreveld
JRJay K. Riva-Cambrin
Jay K. Riva-Cambrin
KLKirstie Lithgow
Kirstie Lithgow
For several decades, dopamine agonist therapy has been the mainstay of treatment for prolactinomas, with surgery generally considered a second line for cases failing medical therapy due to intolerance or resistance. There is increasing recognition of the burden of long-term DA therapy; many patients experience debilitating side effects, and emerging evidence demonstrates that the prevalence of impulse control disorders has been vastly underreported. Long-term DA therapy is associated with significant costs to patients and healthcare systems, which is projected to exceed that of surgery in many circumstances. Recent advancements in surgical approaches, including endoscopic transsphenoidal surgery, have led to improved surgical outcomes (82–100% remission rates; serious complication rates < 2%), prompting a reappraisal of the role of surgery for prolactinoma. Favourable surgical outcomes have been observed in both remission and complication rates for microprolactinomas and well-circumscribed macroprolactinomas, leading to consideration of surgery as an earlier, or first-line, option in the treatment paradigm. Potential advantages of surgical management should be weighed against institutional case volume and expertise, the risk of perioperative complications, and the need for adjuvant medical therapy post-operatively. Ultimately, patients and care-providers should engage in shared decision-making following informed discussion about the risks and benefits of both medical and surgical approaches.

13 April 2025 in Canadian Medical Association Journal
Verified
Journal Article
Open access
JMJenna Mann
Jenna Mann
CBCatherine Bereznicki
Catherine Bereznicki
KLKirstie Lithgow
Kirstie Lithgow

8 April 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JMJenna Mann
Jenna Mann
JGJared Galloway
Jared Galloway
SGSana Ghaznavi
Sana Ghaznavi
DCDavid J. T. Campbell
David J. T. Campbell
JLJohn Lysack
John Lysack
KLKirstie Lithgow
Kirstie Lithgow
Background: Hyperprolactinemia is a common biochemical finding detected in primary care, and guidelines suggest confirmation with a second prolactin measurement to rule out spurious elevation prior to further workup. Premature magnetic resonance imaging (MRI) is a costly potential consequence of improperly worked-up hyperprolactinemia. We aimed to quantify the proportion of prematurely ordered MRI for isolated hyperprolactinemia without confirmation. Methods: A retrospective chart review was performed between 2012–2021 in Alberta, Canada. We identified cases of mildly elevated serum prolactin (18 years who underwent MRI brain or sella following prolactin measurement. MRI was classified as “clinically appropriate” or “premature” based on clinical indication. Clinically appropriate and premature groups were compared based on patient age, sex, and scan year. Results: We identified 1,730 cases meeting inclusion criteria with a single prolactin measurement prior to MRI; over half (56.1%, n = 970) were categorized as “premature.” Of the MRIs in the premature cohort, 39.4% (n = 382) reported at least one abnormal finding, most commonly microadenoma (n = 200). There was no statistically significant difference between premature and clinically appropriate groups for patient sex (p = 0.12) or year of MRI (p = 0.35), but patients in the premature group were significantly older (p < 0.01, mean difference 1.52 years, 95% CI:[0.45,2.49]). Conclusions: MRI for investigation of mild hyperprolactinemia is often ordered prematurely without confirmation by repeat prolactin level and generates incidental findings of uncertain clinical significance to the presenting issue. To reduce patient stress and healthcare system burden, providers should ensure proper workup of hyperprolactinemia with repeat prolactin measurement prior to ordering MRI.

2 June 2026 in Clinical Biochemistry
Verified
Journal Article
Open access
KLKirstie Lithgow
Kirstie Lithgow
JMJenna Mann
Jenna Mann
YSYves P. Starreveld
Yves P. Starreveld
DODennis Orton
Dennis Orton
EVErik S. Venos
Erik S. Venos
GKGregory A. Kline
Gregory A. Kline
Cushing's disease (CD) is a rare disorder of endogenous hypercortisolism arising from a corticotroph adenoma and is associated with significant morbidity and mortality. Measurement of 24-h urine free cortisol (UFC) by liquid chromatography-tandem mass spectrometry (LC-MS/MS) is a recommended first-line screening test. We aimed to evaluate the diagnostic sensitivity of newly established, sex-specific UFC LC-MS/MS reference ranges in a surgical cohort of patients with CD. We performed retrospective analysis of adults undergoing pituitary surgery for confirmed CD at a tertiary center between June 2021 and July 2025. All patients met clinical, biochemical, and radiological criteria for CD. UFC was quantified using an accredited LC-MS/MS assay, according to recently published, sex-specific, optimized reference intervals. Sensitivity of both urine volume-corrected (VC-UFC; nmol/day) and uncorrected (U-UFC; nmol/L) reference ranges were assessed. Sixteen patients (UFC measurements: 28 measurements from 13 females and 8 measurements from 3 males) met inclusion criteria; 88% had histologic confirmation of corticotroph adenoma. Sensitivity of any single UFC measure for CD was 78% (95% CI 61% to 90%); 75% for males (95% CI 25% to 97%) and 79% for females (95% CI 59% to 92%) for VC-UFC and 56% (95% CI 38% to 72%); 88% for males (95% CI 47% to 100%) and 46% for females (95% CI 28% to 66%) for U-UFC. Despite use of LC-MS/MS and rigorously validated reference ranges, UFC demonstrated only modest sensitivity for detecting CD. These findings underscore the limitations of single UFC as a screening test and support the need for multiple collections and complementary biochemical assessments in suspected CD.

15 June 2025 in Canadian Medical Association Journal
Verified
Journal Article
Open access
JMJenna Mann
Jenna Mann
CBCatherine Bereznicki
Catherine Bereznicki
KLKirstie Lithgow
Kirstie Lithgow

12 August 2024 in Cureus
Verified
Journal Article
Open access
PDF file
JMJenna Mann
Jenna Mann
DBDhyey Bhatt
Dhyey Bhatt
MTMichael K. Tso
Michael K. Tso
Melanocytic tumors of the central nervous system (CNS) such as meningeal melanoma are exceedingly rare tumours derived from leptomeningeal melanocytes. We report an illustrative case of a previously healthy 47-year-old male who presented with tonic-clonic seizure. Magnetic resonance imaging (MRI) with contrast demonstrated a homogenously enhancing right temporal extra-axial lesion. The patient was stabilized on anti-epileptic medications and dexamethasone prior to proceeding with complete surgical resection of the lesion. Intraoperatively, the lesion was heavily pigmented with invasion of the surrounding dura and skull. Histopathology revealed a poorly differentiated neoplasm with nuclear atypia and melanin-containing cells with strong SOX10 and variable S100 positivity. Computed tomography (CT) of the chest, abdomen, and pelvis showed no metastatic disease, and molecular profiling was negative including absent BRAF mutation. He began checkpoint inhibitor therapy and subsequently developed cerebral venous sinus thrombosis managed with anticoagulation. Sixteen months post-operatively, he was neurologically intact, working full-time, and had resumed immunotherapy. We systematically reviewed the literature on primary intracranial malignant melanoma (PIMM) with the goal of understanding the prognosis and best treatment options for this disease. Our systematic review produced 82 articles (118 unique cases) of PIMM. The average age at diagnosis was 45.9 years (95% CI:42.9-48.9), and headache (54.2%) was the most common initial presentation. Eighty-nine percent of patients had primary surgical resection, and 41.0% of these individuals experienced a recurrence with a mean time to recurrence of 19.6 months (95% CI:6.95-32.23). Adjuvant therapy was administered in 65.7% of surgically resected patients; including radiotherapy, chemotherapy, immunotherapy, or a combination. In summary, PIMM is a rare tumour that can appear radiographically similar to meningioma. The results of our systematic review demonstrate that surgical resection remains the mainstay of therapy for best long-term prognosis.